eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 65

Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH – case report and review of the literature

Betul Bolat Kucukzeybek
Seyran Yigit
Ayşegul Akder Sari
Turkan Rezanko
Evren Durak
Canan Sadullahoglu

Pol J Pathol 2014; 65 (1): 70-73
Online publish date: 2014/05/13
Article file
- Primary mucinous.pdf  [0.32 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Mucinous cystadenocarcinoma (MCA) is a rare variant of the primary breast carcinomas [1-5]. It is strikingly similar to ovarian and pancreatic counterparts [1, 2, 5]. To our knowledge only 15 cases of primary breast MCAs have been reported up to date in the English literature. Here, we present the clinical, cytological, morphological and immunohistochemical (IHC) features of MCA of the breast in a case of a 55 year old woman, with the review of the relevant literature.

Case report

55-years-old woman was presented to the general surgery department of our hospital upon the palpation of a mass in her left breast. Fine needle aspiration biopsy (FNAB) revealed only a cystic content which was composed of histiocytes. In the FNAB repeated in our department, we observed atypical epithelial cells which tended to form isolated or small groups, with irregular nuclear contours, hyperchromatic nuclei, eosinophilic cytoplasms and few big vacuoles on a basis of debris and bleeding, containing macrophages (Fig. 1A). The patient was suspected to have a malignancy and confirmation with tissue biopsy was recommended. In the excisional biopsy performed, partially cystic irregular tumor in dimensions of 2 × 1 × 1 cm with solid areas was macroscopically observed. Upon microscopic examination, we observed a cystic tumor composed of papillary structures with thin fibrovascular cores that were lined with columnar mucinous cells (Fig. 1B-D).
Histochemically, Alcien Blue positive, dense extracellular and intracellular mucin content was present. Tumoral cells were quite atypical and had prominent nucleoli (Fig. 2A, B). In focal areas, some cells appeared to have decreased content of cytoplasmic mucin and to have large eosinophilic cytoplasma (Fig. 2C).
Around the periphery of the tumor high nuclear grade ductal carcinoma in situ with solid morphology and comedonecrosis was present (Fig. 2D).
Among myoepithelial markers, P63 and smooth muscle actin were negative. Tumoral cells were diffusely positive with cytokeratin 7 (Fig. 3A), whereas cytokeratin 20 (Fig. 3B), p53, ER and PR were all negative. C-erbB2 showed a moderate membranous positivity which was scored as 2 (+) (Fig. 3C). Fluorescent in situ hybridization (FISH) method revealed HER2 gene amplification (Fig. 3D). Ki67 proliferation index of the tumor was 30%. All the 3 sentinal lymphe nodes were free of tumor, therefore axillary dissection was not performed. Upper and lower abdominal CT scans and detailed clinical examination did not reveal any additional pathology. The patient received adjuvant chemotherapy and adjuvant trastuzumab and radiotherapy. During 10-month follow-up, the patient revealed neither recurrence nor metastasis.


Primary MCAs of the breast which was first described by Tavassoli and Koenig in 1998 [1] is a very rare variant of breast tumor. MCA of the breast is histopathologically very similar to its ovarian and pancreatic counterparts [1, 3, 4, 6] and contains both extracellular and intracellular mucin.
Since it is a very entity, differential diagnosis should consider the likelihood of metastasis from other organ tumors [1, 2]. The presence of cytokeratin 7 and cytokeratin 20 in the IHC panel and detailed clinical evaluation are useful for the differential diagnosis of the primary and metastatic mucinous tumors [1, 2, 4]. Ovarian and pancreatic MCAs are cytokeratin 7 (+)/cytokeratin 20 (+), whereas breast MCAs are cytokeratin 7 (+)/cytokeratin 20 (–) [2, 4]. In our case tumoral cells were also cytokeratin 7 (+), cytokeratin 20 (–) which supports that the breast is the primary site of the tumor. In addition, no pathological findings were detected by CT scans or by clinical examination.
Reported cases of MCA of the breast in the literature were all female ranged in age from 41 to 96 years. However most cases were diagnosed during the post-menopausal period.
Tumor diameters ranged between 0.8 cm and 19 cm [1, 2, 4]. Our case was also a 55-years-old woman who was diagnosed during the post-menopausal period and the tumor diameter was 2 cm.
Except one ER positive tumor, all reported cases of MCA were hormone status negative [1, 2, 4, 7-13]. Based on this immunohistochemical finding, primary MCAs of the breast were thought to occur regardless of the estrogenic stimulation [2, 4, 10].
In one case [9], HER2 protein expression and, HER2 gene amplification with FISH method were demonstrated, whereas all other cases were found to have no HER2 protein expression based on IHC [1, 2, 4, 8, 10, 12]. In our case ER and PR were negative and C-erbB2 was 2(+). FISH method revealed HER2 gene amplification. This is the second case that was detected to have HER2 gene amplification in the literature. Among all the cases reported, Ki-67 proliferation index of the tumor was generally high [1, 2]. In our case, Ki-67 proliferation index was 30% and p53 was negative.
Although majority of the reported cases were hormone receptors negative and had high Ki-67 proliferation index [1, 2, 7, 8, 10-12] which indicate poor prognosis, no recurrences and no disease-related death were detected in the follow-ups [2]. Lymph node metastases was only found in three cases [1, 2, 12]. Our case also had no lymph node metastasis and free of disease at 10-months follow-up.
In some cases, DCIS and/or invasive ductal carcinoma were reported in the tissue surrounding the tumor [3, 8, 11]. In our case high nuclear grade DCIS with comedonecrosis was also present in some foci around the periphery of the tumor.
Although the cases of MCA which were reported to be ER, PR and CerbB2 negative and which had a high Ki-67 index were not followed-up long-term, they showed good prognosis [2, 3, 7]. MCA of the breast with different pathogenesis and biological behavior should be differentiated from other histological subtypes of the primary breast cancers and from the metastases of the other organ tumors. The determination of the prognostic features of this very rarely seen variant warrants more case reports with long-term follow-up.
Mucinous cystadenocarcinoma was mentioned as a distinct variant in the 2003 WHO classification of breast tumors. However it was rejected from the classification in WHO 2012 [14]. Although it is rare tumor, owing to the problems in the differential diagnosis and its distinct biological behavior, we think that MCA of the breast merits to take part in the breast tumor classification.


 1. Koenig C, Tavassoli FA. Mucinous cystadenocarcinoma of the breast. Am J Surg Pathol 1998; 22: 698-703.
 2. Honma N, Sakamoto G, Ikenaga M, et al. Mucinous cystadenocarcinoma of the breast: a case report and review of the literature. Arch Pathol Lab Med 2003; 127: 1031-1033.
 3. Chen WY, Chen CS, Chen HC, et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma. Pathol Int 2004; 54: 781-786.
 4. Rakici S, Gönüllü G, Gürsel SB, et al. Mucinous cystadenocarcinoma of the breast with estrogen receptor expression: a case report and review of the literature. Case Rep Oncol 2009; 2: 210-216.
 5. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. The International Agency for Research on Cancer Press. Tavassoli FA, Devilee P (eds.). 1st ed. Lyon 2003; p. 31.
 6. Honma N, Sakamoto G, Ikenaga M, et al. Mucinous cystadenocarcinoma of the breast. A case report and review of literature. Arch Pathol Lab Med 2003; 127: 1031-1033.
 7. Coyne JD, Irion L. Mammary mucinous cystadenocarcinoma. Histopathology 2006; 49: 659-660.
 8. Sentani K, Tashiro T, Uraoka N, et al. Primary mammary mucinous cystadenocarcinoma: cytological and histological findings. Diagn Cytopathol 2012; 40: 624-628.
 9. Petersson F, Pang B, Thamboo TP, Putti TC. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: The first case reported. Hum Pathol 2010; 41: 910-913.
10. Gulwani H, Bhalla S. Mucinous cystadenocarcinoma: A rare primary malignant tumor of the breast. Indian J Pathol Microbiol 2010; 53: 200-202.
11. Domoto H, Terahata S, Yamazaki T, et al. Mucinous cystadenocarcinoma of the breast showing sulfomucin production. Histopathology 2000; 36: 567-569.
12. Deng Y, Xue D, Wang X, et al. Mucinous cystadenocarcinoma of the breast with a basal-like immunophenotype. Pathol Int 2012; 62: 429-432.
13. Kim SE, Hong JH, Jeong JS, Jung WH. Primary mucinous cystadenocarcinoma of the breast: cytologic finding and expression of MUC5 are different from mucinous carcinoma. Korean J Pathol 2012; 46: 611-616.
14. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. World Health Organization Classification of Tumours of the Breast, Fourth Edition (IARC, 2012), p. 8-9.

Address for correspondence
Betul Bolat Kucukzeybek

Department of Pathology
I˙zmir Katip Celebi University Atatürk Training and
Research Hospital
Basinsitesi-Karabaglar-Izmir, Turkey 35360
e-mail: bbkzeybek@yahoo.com
Copyright: © 2014 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe